Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 8/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | ACACA | Q13085 | 1/20 | 0.35 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.33 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12458430 | 1.00 | HPGD (0.36) | HPGDBACE1CCR5ACACBACACA | |
| SCHEMBL14689448 | 1.00 | HPGD (0.36) | HPGDBACE1CCR5ACACBACACA | |
| SCHEMBL12458499 | 0.89 | FFAR4 (0.34) | CCR5ACACBACACANPC1RAB9A | |
| SCHEMBL14689285 | 0.89 | FFAR4 (0.34) | CCR5ACACBACACANPC1RAB9A | |
| SCHEMBL2354489 | 0.89 | FFAR4 (0.34) | CCR5ACACBACACANPC1RAB9A | |
| SCHEMBL28802268 | 0.87 | TSHR (0.32) | KMT2A | |
| SCHEMBL12458492 | 0.85 | BACE1 (0.35) | HPGDBACE1CCR5ACACBACACA | |
| SCHEMBL12049505 | 0.83 | ANO1 (0.47) | HPGDANO1LMNAKMT2A | |
| SCHEMBL12458498 | 0.79 | FFAR4 (0.33) | HPGDCCR5ANO1RAB9AKMT2A | |
| SCHEMBL731914 | 0.78 | ACACB (0.36) | HPGDACACBACACANPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130040935-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| EP-2536686-A1 | CYCLIC KETO-ENOLS FOR THERAPY | Bayer Intellectual Property GmbH (DE) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011098433-A1 | CYCLIC KETO-ENOLS FOR THERAPY | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040935-A1 | CYCLIC KETO-ENOLS FOR THERAPY | AKR1B1, AKR1C3, AKR1A1 | HPGD 90/4885BACE1 3453/4885CCR5 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.